Polymedco Cancer Diagnostic Products LLC

Polymedco Cancer Diagnostic Products LLC, a self-certified small disadvantaged business subsidiary of Polymedco LLC headquartered in Cortlandt Manor, New York, supplies fecal immunochemical testing (FIT) analyzers, collection kits, reagents, consumables, mailing services, and laboratory testing for colorectal cancer screening to the Department of Veterans Affairs and other federal healthcare agencies as a prime contractor (100% of recent awards, no subcontract work).

The vendor's footprint concentrates heavily within the VA's Veterans Integrated Service Networks. The top five funding customer agencies by award count account for 40% of all awards: VISN 16 (85 awards, $11.8 million combined potential value), VISN 10 (67 awards, $3.3 million), VISN 17 (64 awards, $13.7 million), VISN 19 (63 awards, $9.7 million), and VISN 5 (62 awards, $4.5 million). When ranked by potential value, the distribution shifts: VISN 12 anchors 54% of combined potential value across the top five customer agencies at $32.2 million, followed by VISN 2 ($19.2 million), VISN 8 ($16.7 million), VISN 7 ($16.2 million), and VISN 17 ($13.7 million). The gap between award count and dollar concentration reflects a mix of small task orders (reagents, kits, mailing services) against larger IDIQs and BPAs with multi-year ceilings.

Polymedco holds a dominant position on the GSA Federal Supply Schedule vehicle "Critical Analyzers, Laboratory" with 962 task orders totaling $146 million in combined potential value — the overwhelming majority of its federal work. This vehicle anchors the vendor's access to VA procurement across twenty-two distinct customer agencies. Beyond the GSA Schedule, the vendor operates under multiple single-award Indefinite Delivery Contracts with individual VISNs, including a $5.355 million IDIQ with VISN 17 for FIT kit mailing services through January 2030, a $4.5 million IDIQ with VISN 8 for cancer screening products and services through March 2031, a $2.5 million IDIQ with VISN 20 for fecal immunoassay testing through August 2031, and a $1.741 million IDIQ with VISN 21 for fecal occult blood testing through September 2027. A $7.5 million single-award Blanket Purchase Agreement with the Defense Health Agency, effective through September 7, 2030, represents the vendor's primary non-VA vehicle. Polymedco also holds approximately fifteen additional BPAs and IDIQs valued between $250,000 and $1 million with various VISNs.

Recent representative work demonstrates sustained scale. A June 1, 2026 BPA call with the Defense Health Agency valued at $24,000 procured sample bottles for FIT kits. A June 4, 2026 delivery order from VISN 10 carried a $51,676 ceiling for immunochemical fecal occult blood testing. A May 2024 definitive contract from the Indian Health Service for $261,800 procured a Polymedco OC Auto-Sensor iO analyzer, service agreement, reagents, and supplies for the Phoenix Indian Medical Center. A June 2026 delivery order from VISN 20 under a five-year IDIQ valued at $6,480 supported fecal immunoassay testing at VA White City Medical Center; a second VISN 20 order issued the same day carried $96,600 for the same service.

Activity has trended upward — 27 awards in 2022 declining to 18 in both 2023 and 2024, then rising to 34 in 2025 and 21 through September 2026. Twelve awards with ultimate completion dates in the next twenty-four months carry combined potential value of $2.8 million, representing modest recompete exposure. Combined potential value across all 843 prime awards stands at $182.2 million, with $38.3 million obligated to date (21% realization).

The vendor's NAICS posture tracks its product lines: Analytical Laboratory Instrument Manufacturing dominates with 690 of 843 awards, followed by In-Vitro Diagnostic Substance Manufacturing (90 awards), Medical Laboratories (32 awards), and Surgical Appliance and Supplies Manufacturing (21 awards). Top PSC categories align — Reference Laboratory Testing (180 awards), Laboratory Equipment and Supplies (171 awards), and In Vitro Diagnostic Substances, Reagents, Test Kits and Sets (151 awards) — reflecting the vendor's specialization in turnkey FIT solutions including hardware, consumables, and services. The vendor competes full-and-open across nearly all awards; only three awards in the source sample carry small business set-aside designations.

Polymedco operates as a subsidiary of Polymedco LLC, a for-profit parent entity also active in federal contracting. The structure bifurcates work between the parent and subsidiary across some VISN relationships, though consolidated award data treats Polymedco Cancer Diagnostic Products LLC as the predominant federal contracting entity. The vendor's federal footprint reflects established, sole-source market position for proprietary FDA-cleared FIT analyzer platforms (OC-Sensor Diana, OC-Auto Sensor iO, OC-Auto Micro 80) that anchor facility deployments across the VA system, with procurement locked into supply and service continuity around existing installed bases rather than competitive displacement.